Lumen Bioscience

lumen.bio

Lumen Bioscience is a clinical-stage biotechnology company that has reinvented the production of biologic drugs using patented technology that leverages spirulina to create orally delivered therapeutic proteins. Their innovative approach significantly reduces the cost and time associated with drug development, making biologic drugs commercially viable for the first time. Lumen's lead products include LMN-801 for obesity and LMN-201 for C. difficile infections, addressing significant unmet medical needs. With over $84 million invested and 33 issued patents, Lumen is positioned to transform the treatment landscape for metabolic diseases and other prevalent conditions, aiming for global scalability and accessibility.